Royalty Pharma Stock (NASDAQ:RPRX)


ForecastChart

Previous Close

$36.02

52W Range

$24.05 - $38.00

50D Avg

$36.22

200D Avg

$33.52

Market Cap

$15.62B

Avg Vol (3M)

$3.86M

Beta

0.59

Div Yield

$0.87 (2.41%)

RPRX Company Profile


Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

75

IPO Date

Jun 16, 2020

Website

RPRX Performance


Latest Earnings Call Transcripts


Q2 22Aug 04, 22 | 2:09 PM
Q1 22May 05, 22 | 2:09 PM
Q4 21Feb 15, 22 | 11:36 AM

Peer Comparison


TickerCompany
EBSEmergent BioSolutions Inc.
APLSApellis Pharmaceuticals, Inc.
ADPTAdaptive Biotechnologies Corporation
VIRVir Biotechnology, Inc.
LEGNLegend Biotech Corporation
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks